Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.
Core Laboratories Trading Up 1.1 %
Shares of NYSE:CLB opened at $16.33 on Thursday. The stock has a market capitalization of $756.49 million, a PE ratio of 85.95, a P/E/G ratio of 0.76 and a beta of 2.59. Core Laboratories has a 1 year low of $15.21 and a 1 year high of $35.83. The firm has a fifty day moving average price of $18.72 and a 200 day moving average price of $25.10. The company has a current ratio of 2.08, a quick ratio of 1.53 and a debt-to-equity ratio of 1.08.
Core Laboratories (NYSE:CLB - Get Rating) last released its quarterly earnings results on Wednesday, July 27th. The oil and gas company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.02). Core Laboratories had a net margin of 1.82% and a return on equity of 16.12%. The firm had revenue of $120.90 million for the quarter, compared to the consensus estimate of $121.35 million. During the same quarter last year, the company earned $0.18 earnings per share. The firm's revenue was up 1.8% on a year-over-year basis. Analysts expect that Core Laboratories will post 0.54 EPS for the current fiscal year.
Core Laboratories Cuts Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, August 29th. Shareholders of record on Monday, August 8th will be issued a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Friday, August 5th. Core Laboratories's dividend payout ratio (DPR) is 21.05%.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus dropped their price target on shares of Core Laboratories from $26.00 to $20.00 in a research note on Tuesday, July 26th. StockNews.com upgraded shares of Core Laboratories from a "sell" rating to a "hold" rating in a report on Wednesday, May 11th. Finally, Morgan Stanley decreased their price objective on shares of Core Laboratories from $22.00 to $20.00 and set an "equal weight" rating for the company in a report on Monday, August 1st.